PDF电子书：The Delivery of Regenerative Medicines and Their Impact on Healthcare - 经典PDF电子书下载区干细胞之家



免疫细胞治疗专区	欢迎关注干细胞微信公众号

12 3 4 5 6 7 8 9 10 ... 31 下一页

返回列表

查看: 1062028\|回复: 302	go [干细胞与细胞生物学类] PDF电子书：The Delivery of Regenerative Medicines and Their Impact on Healthcare [复制链接]

zsg

注册会员

Rank: 2

积分: 56
威望: 56
包包: 422

楼主

发表于 2013-5-5 09:27 |只看该作者 |倒序浏览 |打印

本帖最后由细胞海洋于 2013-5-6 09:46 编辑 : K2 S/ `2 c: L1 j, L7 z& I

The Delivery of Regenerative Medicines and Their Impact on Healthcare
Edited by
Dr. Catherine D. Prescott
Professor Dame Julia Polak8 y) {: d9 [2 Q" {

Contents
Foreword...................................................................................................................vii! H& ~3 @& `' K6 R! d9 }
Preface.......................................................................................................................ix, U( i% V, {$ C; s
Acknowledgments......................................................................................................xi
About the Editors.................................................................................................... xiii5 E5 Z$ b: X& E8 C5 O! u
Contributors..............................................................................................................xv" S0 ], Y: j4 ?5 v
Section 1 I ntroduction  K" y4 M2 t4 V6 ?: V1 J; U$ D
Chapter 1 What Is Regenerative Medicine?...........................................................31 `! c' U9 @( O* p- R
Julia M. Polak/ g6 q/ V$ M/ I
Section 2 Finance& J% Z4 L9 e2 @, R
Chapter 2 A New Political–Financial Paradigm for Medical Research:
The California Model?........................................................................ 119 r6 ^+ r/ ~  _5 U9 o' F3 S6 T
Robert N. Klein and Alan Trounson
Chapter 3 Investment Models: Public Funding in Australia................................ 35
Graham Macdonald
Chapter 4 Canada: Capitalizing on a 50-Year Legacy......................................... 43
Andrew Lyall
Chapter 5 Investing in Regenerative Medicine: What Drives Private Investors?.... 59
Catherine D. Prescott2 A& f# {8 }9 I
Chapter 6 Public Investment Models: Coming out of the Closet and1 N+ W4 l7 U! \) c/ T
Going Public!...................................................................................... 67# z- u- J# p. e* f. }9 ?. r
Reni Benjamin$ n+ T: [% s& D9 T3 L( }
Section 3 Business Models
Chapter 7 Cell-Based Products: Allogeneic.........................................................85
Paul Kemp$ F& l; x4 B5 R) R+ ^
Chapter 8 Autologous Cell-Based Products: Fulfilling the Promise of) I( B& {9 h. J: w
Cell Therapy........................................................................................97
Eduardo Bravo and Magdalena Blanco-Molina- l' {; l7 v& m1 L
Chapter 9 Business Models for Cord Blood....................................................... 1179 N+ u( |1 |9 Y/ ^! d# g
Suzanne M. Watt1 i1 P; ^! I; d$ ]% C
Chapter 10 Changing the Game of Drug Discovery............................................ 131# l; ^) F5 i0 T  Q: ^. w- X% ^
John Walker
Chapter 11 Discovery of Small Molecule Regenerative Drugs........................... 141- d2 g1 j2 p0 X9 [
Yen Choo
Chapter 12 Adoption of Therapeutic Stem Cell Technologies by Large
Pharmaceutical Companies............................................................... 1533 i3 [; l0 \. o
Alain A. Vertès* s" l" A/ ]1 {3 y5 F* Y
Chapter 13 Role of Tool and Technology Companies in Successful
Commercialization of Regenerative Medicine.................................. 177
Joydeep Goswami and Paul Pickering+ [# I+ M- e2 p8 m% s* ^. x1 H8 A
Chapter 14 Key Considerations in Manufacturing of Cellular Therapies........... 189, l+ X+ \) f9 _! P0 o, U) S* a1 ], U( Q
Robert A. Preti3 Q1 X4 J8 Q! g( x2 h! a
Chapter 15 State of the Global Regenerative Medicine Industry........................ 213
R. Lee Buckler, Robert Margolin, and Sarah A. Haecker
Section 4 Intellectual Property
Chapter 16 Regenerating Intellectual Property: Europe after WARF................. 239
Julian Hitchcock and Devanand Crease
Chapter 17 Protecting Regenerative Medicine Intellectual Property in the" B" j% c" a1 Y
United States: Problems and Strategies............................................. 2573 Z- o3 k, Y# G! B. p
David Resnick, Ronald I. Eisenstein, and Joseph M. McWilliams
Chapter 18 Impacts of Indian Policies and Laws on Regenerative
Medicine Patent Applications........................................................... 281
Prabuddha Ganguli
Section 5 Regulatory Landscape9 c+ L* r5 l# A4 J, y( T
Chapter 19 A CATalyst for Change: Regulating Regenerative Medicines in* \$ z* |+ l9 E
Europe...............................................................................................295
Christopher A. Bravery
Chapter 20 United States Regulatory Reimbursement, Political
Environment, and Strategies for Reform........................................... 323
Michael J. Werner
Section 6 Reimbursement
Chapter 21 The Fourth Hurdle: Reimbursement Strategies for8 {1 M" J3 M( b' M3 T  e7 \9 G
Regenerative Medicine in Europe..................................................... 337
François M. Meurgey and Micheline Wille
Chapter 22 Cellular Therapies and Regenerative Medicine: Preparing for0 v. v& b, T* C& s% c. `! J
Reimbursement in the United States................................................. 3510 v7 l; j2 I9 Q$ S) n  Z7 |
Eric Faulkner
Chapter 23 Adoption and Evaluation of Regenerative Medicine and the
National Health Service....................................................................3695 n7 V: t& a/ M, n8 d9 y
Margaret Parton+ k( I: D( k" ^' X% @
Section 7 I nsurance and Risk Management9 V+ ?, b+ f4 @
Chapter 24 Role of Insurance: If You Build It, Will They Insure It?.................. 379/ n: z$ D" f* y8 Q; T2 U
Matthew Clark
Index....................................................................................................................... 391+ {9 h8 O. Q, z2 H# w
, t- y; P2 b6 t1 ]! U
[hide][/hide]

附件: 你需要登录才可以下载或查看附件。没有帐号？注册